On May 8, 2026, Anjin registered the GIPR antibody coupled GLP-1 new drug AMG 133 (Maridebart Caffraglutide) on the Clinicaltrials.gov website for the maintenance therapy phase III clinical trial MARITIME-SWITCH after GLP-1 treatment.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
We provide GLP-1 Injections, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html.
The Phase III clinical plan will enroll 300 subjects and is expected to be completed by January 2028.
The inclusion criteria for this Phase III clinical trial are a population with BMI225 (non obesity criteria above 30) and a weight loss rate of over 10% after GLP-1 treatment. From the primary endpoint and secondary efficacy endpoint, the daily goal of this phase III clinical trial is to maintain the weight loss effect of GLP-1 through AMG133, that is, to control rebound.
AMG 133 (Maridebart Caffraglutide) is the world's first GIPR antibody conjugated GLP-1 drug developed by Amgen. It adopts a unique structure of GIPR antagonist antibody coupled with GLP-1 agonist peptide, which is different from conventional GLP-1/GIP dual agonists. By activating GLP-1 receptors to suppress appetite and blocking GIP receptors to weaken lipophilic effects, it achieves strong weight loss
Roche GLP-1R/GIPR dual agonist RO7795068 injection received implied CDE approval for domestic clinical application
Recently, the official website of China National Center for Drug Evaluation (CDE) showed that Roche's clinical trial application for Class 1 new drug RO7795068 injection has been granted implied permission. The proposed indication is: suitable for long-term weight management of obese or overweight adult patients based on controlling diet and increasing exercise.
RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion and obtained the product. The Insight database shows that the obesity indication for RO7795068 has advanced to Phase III clinical stage overseas.
The Phase II results showed that subcutaneous injection of RO7795068 once a week (gradually increasing the dose to 24mg) significantly reduced the patient's weight by 22.5% (estimated efficacy), and did not reach the weight loss plateau at week 48.
The study observed a significant dose-response relationship between weight loss and dosage. In the analysis of treatment plan estimates, RO7795068 achieved a placebo corrected weight loss of 18.3% (p<0.001).
Xingrui Pharmaceutical has completed nearly $40 million in Series B+financing to deepen its focus on mRNA innovative therapies
Recently, Starna Therapeutics announced the completion of nearly $40 million in Series B+funding. This round of financing is jointly invested by well-known industry funds, Hillhouse Capital, LYVFE Capital, LAV, Sherpa Investment, Source Code Capital, and Chunhua Capital.
After completing a Series B financing of $44 million, the company has once again received support from well-known institutions after half a year. The funds from this tomb collection will be focused on accelerating the clinical development of multiple pipelines for in vivo CAR-T cell therapy, promoting the construction of extrahepatic delivery platforms for the lungs, intestines, and nervous system, and consolidating and strengthening the company's innovative research and development layout in the field of mRNA therapy.
Zhengda Tianqing joins hands with GSK! The first ASO drug Bepirovirsen accelerates the functional cure of hepatitis B
On May 11, 2026, China Biopharmaceutical (1177. HK) officially announced that the core enterprise Zhengda Tianqing and GlaxoSmithKline (GSK) have reached an exclusive strategic cooperation, which will accelerate the marketing process of the same kind of pioneering (FIC) new drug Bepirovirsen in China. At the beginning of this year, Bepirovirsen has submitted an application for marketing to the Drug Evaluation Center (CDE) of the National Drug Administration, and has been included in the list of priority evaluation varieties. It is expected to become the first drug to achieve the functional cure of chronic hepatitis B, bringing a revolutionary breakthrough in the domestic hepatitis B treatment field.
According to the terms of the agreement, Zhengda Tianshi will be responsible for the import, distribution, hospital access, promotion, and non promotion activities of Bepiovirsen in mainland China. All sales revenue generated from this product will be recognized as Zhengda Tianshi's operating revenue. GSK will continue to serve as the Marketing Authorization Holder (MAH) for drugs, responsible for overseeing registration affairs, quality control, drug vigilance, and global medical strategies. Both parties will also have the opportunity to further explore cooperation on the R&D pipeline assets of our group that are seeking cooperation opportunities in markets outside of China. This cooperation will support both parties in establishing a long-term partnership and provide a solid foundation for further expanding innovation asset cooperation in the future.
Bepirovesen is a first of its kind antisense nucleotide (ASO) with a triple mechanism, used for the treatment of adult chronic hepatitis B (CHB). It was included in the breakthrough treatment drug program by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration in August 2021 and was included in the priority review and approval process in April 2026. Bepirovesen demonstrated statistically and clinically significant functional cure rates in the B-Well1 and B-Wel 2 Phase III clinical trials, supporting the submission of marketing applications.